IHMA, Schaumburg, Illinois, USA.
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0199021. doi: 10.1128/AAC.01990-21. Epub 2021 Nov 22.
We report susceptibility data from five consecutive annual SIDERO-WT surveillance studies (2014 to 2019) for cefiderocol and comparators tested against Gram-negative clinical isolates from North America and Europe. CLSI broth microdilution was used to determine MICs for (= 31,896), Pseudomonas aeruginosa (= 7,700), Acinetobacter baumannii complex (= 5,225), Stenotrophomonas maltophilia (= 2,030), and Burkholderia cepacia complex (= 425). MICs were interpreted by CLSI-approved clinical breakpoints (February 2021). Cefiderocol inhibited 99.8, 96.7, 91.6, and 97.7% of all , meropenem-nonsusceptible, ceftazidime-avibactam-nonsusceptible, and ceftolozane-tazobactam-nonsusceptible isolates, respectively, at ≤4 μg/mL (susceptible breakpoint). Cefiderocol inhibited 99.9, 99.8, 100, and 99.8% of all P. aeruginosa, meropenem-nonsusceptible, ceftazidime-avibactam-nonsusceptible, and ceftolozane-tazobactam-nonsusceptible isolates, respectively, at ≤4 μg/mL (susceptible breakpoint). Cefiderocol inhibited 96.0% of all A. baumannii complex isolates and 94.2% of meropenem-nonsusceptible isolates at ≤4 μg/mL (susceptible breakpoint) and 98.6% of S. maltophilia isolates at ≤1 μg/mL (susceptible breakpoint). B. cepacia complex isolates were tested with a MIC of ≤0.03 μg/mL and MIC of 0.5 μg/mL. Annual cefiderocol percent susceptible rates for (North America range, 99.6 to 100%/year; Europe range, 99.3 to 99.9%/year) and P. aeruginosa (North America range, 99.8 to 100%; Europe range, 99.9 to 100%) were unchanged from 2014 to 2019. Annual percent susceptible rates for A. baumannii complex demonstrated sporadic, nondirectional differences (North America range, 97.5 to 100%; Europe range, 90.4 to 97.5%); the wider range for Europe (∼7%) was due to isolates from Russia. Annual percent susceptible rates for S. maltophilia showed minor, nondirectional differences (North America range, 96.4 to 100%; Europe range, 95.6 to 100%). We conclude that clinical isolates of (99.8% susceptible), P. aeruginosa (99.9%), A. baumannii (96.0%), and S. maltophilia (98.6%) collected in North America and Europe from 2014 to 2019 were highly susceptible to cefiderocol.
我们报告了连续五年（2014 年至 2019 年）进行的 SIDERO-WT 监测研究中头孢地尔的药敏数据，这些研究针对来自北美和欧洲的革兰氏阴性临床分离株进行了检测。使用 CLSI 肉汤微量稀释法测定头孢地尔和对照药物对 (=31,896)、铜绿假单胞菌 (=7,700)、鲍曼不动杆菌复合群 (=5,225)、嗜麦芽窄食单胞菌 (=2,030)和洋葱伯克霍尔德菌复合群 (=425)的 MIC。MIC 解释采用 CLSI 批准的临床折点（2021 年 2 月）。头孢地尔对所有 <=4μg/ml（敏感折点）的 、美罗培南不敏感、头孢他啶-阿维巴坦不敏感和头孢洛扎-他唑巴坦不敏感的分离株的抑制率分别为 99.8%、96.7%、91.6%和 97.7%。头孢地尔对所有 <=4μg/ml（敏感折点）的铜绿假单胞菌、美罗培南不敏感、头孢他啶-阿维巴坦不敏感和头孢洛扎-他唑巴坦不敏感的分离株的抑制率分别为 99.9%、99.8%、100%和 99.8%。头孢地尔对所有鲍曼不动杆菌复合群分离株的抑制率为 96.0%，对美罗培南不敏感的分离株的抑制率为 94.2%，所有嗜麦芽窄食单胞菌分离株的抑制率为 98.6%，均<=1μg/ml（敏感折点）。洋葱伯克霍尔德菌复合群分离株的 MIC 测试浓度为 <=0.03μg/ml 和 0.5μg/ml。2014 年至 2019 年， （北美范围为 99.6%至 100%/年；欧洲范围为 99.3%至 99.9%/年）和铜绿假单胞菌（北美范围为 99.8%至 100%；欧洲范围为 99.9%至 100%）的头孢地尔年敏感率保持不变。鲍曼不动杆菌复合群的年敏感率显示出零星的、无方向的差异（北美范围为 97.5%至 100%；欧洲范围为 90.4%至 97.5%）；欧洲的范围较宽（约 7%）是由于来自俄罗斯的分离株所致。嗜麦芽窄食单胞菌的年敏感率显示出较小的、无方向的差异（北美范围为 96.4%至 100%；欧洲范围为 95.6%至 100%）。我们的结论是，2014 年至 2019 年在北美和欧洲收集的 （99.8%敏感）、铜绿假单胞菌（99.9%敏感）、鲍曼不动杆菌（96.0%敏感）和嗜麦芽窄食单胞菌（98.6%敏感）的临床分离株对头孢地尔高度敏感。
